Prescribing information

 

__

Fatima, a 49-year-old woman previously diagnosed with relapsing-remitting multiple sclerosis (RRMS), is concerned about worsening balance and neuropathic pain. Review her case study from 2019 below to make your own assessment as to whether she may have transitioned to SPMS with active disease and decide on the best course of action for her care.

Throughout Fatima’s case study you will find multiple choice questions. These do not have correct answers but are designed to support your clinical assessment of Fatima’s case and to simulate a real-life clinical decision-making situation with a patient.

Beneath the case study you can watch a video of MS expert Dr Emma Tallantyre, clinical senior lecturer at Cardiff University, discussing the key characteristics of the case. Dr Tallantyre also explains how she would manage the case in the clinic and provides her assessment for Fatima.

Watch Dr Tallantyre’s assessment of Fatima’s case

 

*Indication: Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.

MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.

Reference

  1. MAYZENT (siponimod) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | January 2022 | 164594
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]